Segall Bryant & Hamill LLC Boosts Position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Segall Bryant & Hamill LLC boosted its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 18.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 168,882 shares of the company's stock after acquiring an additional 26,843 shares during the period. Segall Bryant & Hamill LLC owned about 0.31% of PROCEPT BioRobotics worth $9,839,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of PRCT. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of PROCEPT BioRobotics by 9.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,779 shares of the company's stock valued at $527,000 after purchasing an additional 723 shares during the last quarter. Sei Investments Co. increased its position in PROCEPT BioRobotics by 189.2% during the fourth quarter. Sei Investments Co. now owns 95,315 shares of the company's stock worth $7,675,000 after buying an additional 62,359 shares during the period. Vanguard Group Inc. lifted its stake in PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock valued at $413,907,000 after buying an additional 297,075 shares during the last quarter. GAMMA Investing LLC lifted its stake in PROCEPT BioRobotics by 7,021.1% in the first quarter. GAMMA Investing LLC now owns 6,409 shares of the company's stock valued at $373,000 after buying an additional 6,319 shares during the last quarter. Finally, Bessemer Group Inc. boosted its holdings in shares of PROCEPT BioRobotics by 50.7% in the first quarter. Bessemer Group Inc. now owns 10,900 shares of the company's stock valued at $635,000 after acquiring an additional 3,665 shares during the period. Institutional investors and hedge funds own 89.46% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Oppenheimer began coverage on shares of PROCEPT BioRobotics in a report on Monday, July 7th. They issued a "market perform" rating on the stock. Stephens initiated coverage on shares of PROCEPT BioRobotics in a report on Wednesday, July 9th. They issued an "overweight" rating and a $70.00 target price for the company. Truist Financial decreased their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. Morgan Stanley lowered their price target on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a report on Tuesday. Finally, Wall Street Zen downgraded PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, PROCEPT BioRobotics has an average rating of "Moderate Buy" and a consensus target price of $84.13.

PROCEPT BioRobotics Stock Down 1.0%

NASDAQ PRCT traded down $0.58 during trading hours on Friday, hitting $58.35. 1,834,155 shares of the stock were exchanged, compared to its average volume of 854,800. The company has a current ratio of 8.95, a quick ratio of 7.75 and a debt-to-equity ratio of 0.13. PROCEPT BioRobotics Corporation has a 12-month low of $47.04 and a 12-month high of $103.81. The stock has a 50-day moving average of $58.73 and a 200 day moving average of $62.06.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.04. The company had revenue of $69.16 million for the quarter, compared to analysts' expectations of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 28.09% and a negative net margin of 36.20%. The firm's quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.51) EPS. Sell-side analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Insider Activity at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 25,000 shares of the firm's stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $61.49, for a total value of $1,537,250.00. Following the completion of the sale, the director owned 14,363 shares in the company, valued at $883,180.87. This trade represents a 63.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 100,000 shares of company stock worth $6,271,250. 6.60% of the stock is currently owned by insiders.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).